Immutep Limited (ASX:IMM) Executive Director and CEO Marc Voigt, Chief Medical Officer Dr Florian Vogl, and Senior Vice President Strategic Development Christian Mueller present on Immutep’s latest clinical results.
Key points:
- Efti in combination with KEYTRUDA (pembrolizumab) achieved a 35.5% response rate in evaluable patients (N=31), according to RECIST 1.1, among the highest recorded for a treatment approach not containing chemotherapy in patients with CPS <1
- High complete response rate of 9.7% with three patients showing a disappearance of cancer lesions post treatment
- Durability of responses tracks well and over 50% of patients received treatment for at least six months
- Combination continues to have a favourable safety profile with no new safety signals observed
- Based on encouraging results and high unmet medical need, the path forward will be discussed with regulatory agencies
